Niosomes (nonionic surfactant-based vesicles) containing rifampicin were prepared using various nonionic surfactants of sorbitan ester class and cholesterol in 50:50 percent mol fraction ratio. The drug-entrapped vesicles were characterized for their shape, size, drug entrapment efficiency and in vitro release rate. On the basis of in vitro characterization, the niosomes showing maximum entrapment and minimum release rate were selected for in vivo performance evaluation. Cumulative percent doses of rifampicin recovered in thoracic lymph following intravenous and intraperitoneal administrations of free rifampicin solution and niosome-encapsulated rifampicin were compared. The study revealed that effective compartmentalisation of the drug took place in the lymphatic system following intraperitoneal administration of niosome-encapsulated rifampicin. Thus rifampicin encapsulated in niosomes could successfully be used for treatment of tuberculosis along lymphatic system.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2006) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: